Chong Kun Dang Pharmaceutical Market Cap ($533.97 Million)
Market Cap & Net Worth: Chong Kun Dang Pharmaceutical (185750)
Chong Kun Dang Pharmaceutical market cap. Chong Kun Dang Pharmaceutical (KO:185750) has a market capitalization of $533.97 Million (₩787.93 Billion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #11550 globally and #311 in its home market, demonstrating a -7.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chong Kun Dang Pharmaceutical's stock price ₩59800.00 by its total outstanding shares 13176068 (13.18 Million). Also see Chong Kun Dang Pharmaceutical cash conversion from operations for how efficiently the company converts equity into cash flow.
Chong Kun Dang Pharmaceutical Market Cap History (2015–2026)
Chong Kun Dang Pharmaceutical market cap history from 2015 to 2026. Data shows growth from $570.44 Million to $533.97 Million (3.18% CAGR). Check Chong Kun Dang Pharmaceutical stock quote for real-time trading data and today's change.
Chong Kun Dang Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chong Kun Dang Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 185750 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Chong Kun Dang Pharmaceutical's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Chong Kun Dang Pharmaceutical's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $625.56 Million | $831.99 Billion | $40.95 Billion | 0.00x | 0.02x |
| 2017 | $834.57 Million | $884.36 Billion | $53.81 Billion | 0.00x | 0.02x |
| 2018 | $683.64 Million | $956.22 Billion | $42.40 Billion | 0.00x | 0.02x |
| 2019 | $688.98 Million | $1.08 Trillion | $53.88 Billion | 0.00x | 0.01x |
| 2020 | $1.70 Billion | $1.30 Trillion | $91.63 Billion | 0.00x | 0.02x |
| 2021 | $880.91 Million | $1.34 Trillion | $42.72 Billion | 0.00x | 0.02x |
| 2022 | $692.14 Million | $1.49 Trillion | $80.95 Billion | 0.00x | 0.01x |
| 2023 | $1.17 Billion | $1.67 Trillion | $212.52 Billion | 0.00x | 0.01x |
| 2024 | $794.70 Million | $1.59 Trillion | $109.07 Billion | 0.00x | 0.01x |
| 2025 | $740.23 Million | $1.69 Trillion | $77.51 Billion | 0.00x | 0.01x |
Competitor Companies of 185750 by Market Capitalization
Companies near Chong Kun Dang Pharmaceutical in the global market cap rankings as of November 3, 2026. Also see Chong Kun Dang Pharmaceutical assets under control for a full breakdown of the balance sheet.
Key companies related to Chong Kun Dang Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Chong Kun Dang Pharmaceutical (2015–2026)
Market capitalization of Chong Kun Dang Pharmaceutical from 2015 to today. Between 2015 and today, Chong Kun Dang Pharmaceutical's market cap moved from $570.44 Million to $ 533.97 Million, with a yearly change of 3.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩533.97 Million | -27.86% |
| 2025 | ₩740.23 Million | -6.85% |
| 2024 | ₩794.70 Million | -32.01% |
| 2023 | ₩1.17 Billion | +68.87% |
| 2022 | ₩692.14 Million | -21.43% |
| 2021 | ₩880.91 Million | -48.09% |
| 2020 | ₩1.70 Billion | +146.32% |
| 2019 | ₩688.98 Million | +0.78% |
| 2018 | ₩683.64 Million | -18.08% |
| 2017 | ₩834.57 Million | +33.41% |
| 2016 | ₩625.56 Million | +9.66% |
| 2015 | ₩570.44 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Chong Kun Dang Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $533.97 Million USD |
| MoneyControl | $533.97 Million USD |
| MarketWatch | $533.97 Million USD |
| marketcap.company | $533.97 Million USD |
| Reuters | $533.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more